Our mission is to shape the future of drug discovery with massively parallel supercomputing, lightning fast quantum chemistry, and superhuman machine intelligence.
Loong Wang
Cofounder and CEO
Cofounder and CEO
Loong Wang received his training in research and development in computer science at the Australian National University, specializing in mathematics and distributed supercomputing. In 2017, he co-founded two startups in deep-tech and fintech, successfully raising over $50 million within four years.
He is also a co-founder of Automera, a therapeutics company developing a targeted autophagy-driven degradation platform.
He is also dedicated to philanthropy, supporting entrepreneurship among university students and providing scholarships for computer scientists transitioning into biotechnology. He currently serves as the Chief Executive Officer of QDX and the Chief Technology Officer of Automera.
He is also a co-founder of Automera, a therapeutics company developing a targeted autophagy-driven degradation platform.
He is also dedicated to philanthropy, supporting entrepreneurship among university students and providing scholarships for computer scientists transitioning into biotechnology. He currently serves as the Chief Executive Officer of QDX and the Chief Technology Officer of Automera.
Taiyang Zhang
Cofounder
Cofounder
Taiyang Zhang is a co-founder of QDX and has a background in computer science.
He is a co-founder of Automera, a therapeutics company developing a novel therapeutic approach via autophagy-based targeted protein degradation. Automera secured $16 million in Series A funding in 2023.
Alongside Loong Wang, he established the Talo Computational Biology Talent Accelerator at the Australian National University, which provides PhD scholarships and innovator grants to researchers.
He is a co-founder of Automera, a therapeutics company developing a novel therapeutic approach via autophagy-based targeted protein degradation. Automera secured $16 million in Series A funding in 2023.
Alongside Loong Wang, he established the Talo Computational Biology Talent Accelerator at the Australian National University, which provides PhD scholarships and innovator grants to researchers.
Dr Kelvin Neu
Cofounder
Cofounder
Dr. Kelvin Neu is a co-founder of QDX and a twenty-plus-year veteran of life sciences investing and innovation.
A physician-scientist by training, he holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology PhD program at Stanford University. Kelvin also holds an AB from Princeton, where he graduated summa cum laude and was awarded the Khoury Prize for topping his department of Molecular Biology.
Kelvin was previously a Partner at Baker Bros Advisors, a leading US-based life sciences investment firm, where he spent almost two decades. He has served on the boards of many private and public biotech companies, has extensive networks within the industry, and plays a key role in guiding QDX’s strategic direction. Outside of QDX, Kelvin runs Herringbone, a life sciences innovation practice that engages broadly with the global life sciences ecosystem.
A physician-scientist by training, he holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology PhD program at Stanford University. Kelvin also holds an AB from Princeton, where he graduated summa cum laude and was awarded the Khoury Prize for topping his department of Molecular Biology.
Kelvin was previously a Partner at Baker Bros Advisors, a leading US-based life sciences investment firm, where he spent almost two decades. He has served on the boards of many private and public biotech companies, has extensive networks within the industry, and plays a key role in guiding QDX’s strategic direction. Outside of QDX, Kelvin runs Herringbone, a life sciences innovation practice that engages broadly with the global life sciences ecosystem.
A/Prof Giuseppe Barca
Cofounder and Head of R&D
Cofounder and Head of R&D
A/Prof. Giuseppe Barca is an expert in high-performance computing (HPC), artificial intelligence (AI), and digital chemistry. He has led significant collaborations, enhancing molecular modeling globally. From 2018 to 2023, he directed Australia’s involvement in the US Department of Energy’s Exascale Computing Projects and the Pawsey Centre for Extreme-scale Readiness (PaCER) projects.
His research focuses on HPC algorithms and machine learning models for predicting the physical chemistry of large molecular systems. His team’s AI-driven quantum mechanical software is widely used in industry and academia.
A/Prof. Barca’s team set records in HPC for the largest computational quantum chemical modeling, using over 27,000 GPUs on the Summit supercomputer and 37,000 GPUs on the Frontier system, the first exascale computer. This work has advanced drug development through quantum-accurate molecular modeling.
In 2024, A/Prof. Barca was named one of Australia’s Top 250 Researchers by The Australian for his impactful research and significant citation record.
His research focuses on HPC algorithms and machine learning models for predicting the physical chemistry of large molecular systems. His team’s AI-driven quantum mechanical software is widely used in industry and academia.
A/Prof. Barca’s team set records in HPC for the largest computational quantum chemical modeling, using over 27,000 GPUs on the Summit supercomputer and 37,000 GPUs on the Frontier system, the first exascale computer. This work has advanced drug development through quantum-accurate molecular modeling.
In 2024, A/Prof. Barca was named one of Australia’s Top 250 Researchers by The Australian for his impactful research and significant citation record.
Together, we can shape the future.
Work with us
